July 15, 2025: NCHR submitted written comments to the U.S. Food and Drug Administration in support of the proposed rule on front-of-package nutrition labeling, recommending stronger, clearer labeling requirements, especially for young children. They suggested additional testing to ensure consumers understand and benefit from the labels, including those with limited literacy or English proficiency.
Read More »On Health Policy
PDUFA VIII Statement of Dr. Amanda Berhaupt, Health Policy Director of NCHR
July 14, 2025: NCHR presentation at PDUFA July 2025 user fee meeting focuses on including patients and consumers in negotiations with FDA and industry and adding metrics to ensure post-market safety and meaningful clinical outcomes for prescription drugs.
Read More »GDUFA IV Statement of Dr. Diana Zuckerman, President of NCHR
July 11, 2025: NCHR presentation at GDUFA IV July 2025 user fee meeting focuses on including patients and consumer in negotiations with FDA and industry and including metrics to show improved safety and equivalence for generic drugs.
Read More »NCHR signed on to letter urging the OSTP to provide public comment opportunities
June 20, 2025: NCHR and other non-profit organizations sent a letter to the director of the Office of Science Technology Policy urging them to uphold scientific integrity and explaining that opportunities to provide input will increase public trust in scientific decisions.
Read More »NCHR Follow-up to DC Council Environmental Health Hazards Roundtable
May 19, 2025: NCHR submitted a letter for the hearing record for the D.C. Council roundtable about environmental and safety hazards in DC parks and playgrounds. Our letter provided the requested information in response to questions about whether artificial turf is recycled and shared additional information about research indicating the presence of heavy metals on rubber playground surfaces.
Read More »